

SkQ1 shows promise in dry eye syndrome

"Significant positive results" have been shown from a U.S. phase 2 clinical trial of SkQ1 in patients with moderate to severe dry eye syndrome, developer Mitotech (Luxembourg) said in a news release.

SkQ1 is the first mitochondria-targeted antioxidant to reach clinical phase of development for an ophthalmic indication, the company said. The phase 2 study achieved statistically significant treatment effects in both signs and symptoms of dry eye syndrome in the intent-to-treat population (n=90).

SkQ1 demonstrated superiority over placebo in several endpoints such as central ($P=0.036$) and total corneal ($P=0.045$) fluorescein staining pre- to post-Controlled Adverse Environment (CAE) and grittiness ($P=0.058$) pre- to post-CAE at week 4 in the intent-to-treat population.

An ophthalmic formulation of SkQ1 is already marketed in Russia as Visomitin. A phase 3 study in the U.S. is expected to begin during the fourth quarter.